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Introduction
In 1985, a National Institutes of Health (NIH) consensus
conference was convened to evaluate data obtained from
randomized clinical trials of adjuvant chemotherapy and
endocrine therapy that had been conducted during the 1970s
and early 1980s.1 At that meeting, it was concluded that
premenopausal patients with primary breast cancer and
positive axillary lymph nodes should be treated with adjuvant
chemotherapy. There was not much information about
adjuvant therapy for women with negative axillary lymph
nodes. The value of adjuvant endocrine therapy in
premenopausal breast cancer patients who received adjuvant
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chemotherapy is not yet confirmed.2 Endocrine therapy has
been widely used in the adjuvant setting for oestrogen receptor
(ER)-positive patients due to its high efficacy and minimal
toxicity. Tamoxifen (TAM) has changed the treatment of breast
cancer and it is now the gold standard of adjuvant endocrine
therapy for breast cancer patients. Currently, adjuvant TAM is
commonly used for postmenopausal patients, and it is also
accepted that adjuvant TAM without chemotherapy can
improve disease-free survival (DFS) and overall survival (OS)
in premenopausal breast cancer patients.
The purpose of our study was to evaluate the value of
adjuvant endocrine therapy in premenopausal breast cancer
patients who received adjuvant chemotherapy through the
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OBJECTIVE: To study the value of adjuvant tamoxifen (TAM) in premenopausal women with oestrogen receptor
(ER)-positive breast cancer who received adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF)
polychemotherapy.
METHODS: Four hundred and two premenopausal ER-positive breast cancer patients who received CMF
chemotherapy between January 1990 and December 1999 were retrospectively studied. Disease-free survival
(DFS) and overall survival (OS) were used to evaluate the clinical value of TAM therapy. The relationships between
nodal status and TAM were also analysed.
RESULTS: After a mean of 41 months of follow-up, 43 (13.7%) patients died of breast cancer and 68 (19.9%)
patients suffered recurrence. There was a significant difference between TAM and non-TAM treatment groups for
DFS (p = 0.0058), but no significant difference for OS. For node-negative patients, there was no significant
difference between the TAM and non-TAM treatment groups for either DFS or OS. For node-positive patients,
the difference between TAM and non-TAM treatment groups was significant for both DFS and OS (p = 0.0497 and
p = 0.0285, respectively).
CONCLUSION: TAM resulted in additional benefit to premenopausal patients with node-positive ER-positive
breast cancer who received the CMF polychemotherapy regimen. [Asian J Surg 2003;26(3):163–8]
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analysis of TAM’s efficacy. In the present study, 402 ER-
positive premenopausal breast cancer patients who received
cyclophosphamide, methotrexate and 5-fluorouracil (CMF)
polychemotherapy between January 1990 and December 1999
were retrospectively studied. We tried to identify subgroups
of premenopausal patients for whom adjuvant TAM should
be used.
Patients and methods
Patient accrual standard
Medical records from January 1990 to December 1999, from
the Cancer Hospital, Shanghai, China, were retrospectively
reviewed for premenopausal patients with operable breast
cancer without evidence of metastasis who received adjuvant
CMF polychemotherapy. During that time, 865 premenopausal
women with primary, operable breast cancer and no evidence
of metastatic disease were identified (axillary node involve-
ment were not considered metastases). Among the 865 patients,
402 ER-positive patients received adjuvant CMF polyche-
motherapy.
Study information
The end points used for analysis were DFS and OS. The mean
follow-up time for the 402 patients studied was 41 months
(range, 12–120 months). All 402 patients underwent radical
mastectomy or modified radical mastectomy, followed by
adjuvant CMF chemotherapy. The CMF regimen and hormonal
regimen were as follows: cyclophosphamide (CTX)
600 mg/m2, methotrexate (MTX) 40 mg/m2 and 5-fluorouracil
(5-Fu) 600 mg/m2 were given intravenously on days 1 and 8
per 28 days for six cycles; after the six cycles of CMF, 20 mg/day
TAM was administered orally for 3 years (Table 1).
Patient characteristics
The 402 patients ranged in age from 24 to 53 years (mean, 43
years). Of the 402 patients, 189 (47%) had negative axillary
lymph nodes, while 213 (53%) had positive nodes. The number
of stage I, II, and III patients were 91 (23%), 262 (65%) and
49 (12%), respectively. Among the 402 patients, 118 received
adjuvant TAM after chemotherapy (TAM group), while
284 received no endocrine therapy (non-TAM group).
Characteristics of the 402 patients are shown in Table 2.
In the 1990s, there were three groups of doctors in our
department. To evaluate the efficacy of TAM in premeno-
pausal women with ER-positive breast cancer who had received
adjuvant CMF polychemotherapy, one group treated the
Table 1. Drug doses and schedules
CMF (every 4 weeks x 6 cycles)
   Cyclophosphamide 600 mg/m2, Days 1 and 8
   iv short infusion
   Methotrexate 40 mg/m2, Days 1 and 8
   iv bolus
   5-Fluorouracil 600 mg/m2, Days 1 and 8
   iv bolus
CMF + TAM (every 4 weeks x 6 cycles)
   Cyclophosphamide 600 mg/m2, Days 1 and 8
   iv short infusion
   Methotrexate 40 mg/m2, Days 1 and 8
   iv bolus
   5-Fluorouracil 600 mg/m2, Days 1 and 8
   iv bolus
   Tamoxifen 10 mg, po bid Administered after
   6 cycles of CMF
CMF = cyclophosphamide + methotrexate + 5-fluorouracil; TAM =
tamoxifen.
patients who had TAM therapy and the other two groups of
doctors treated the patients who did not have TAM therapy.
As the role of TAM in these specific patients was not con-
firmed, informed consent was obtained from the patients who
received TAM.
Statistical considerations
In the analysis of DFS, an event was defined as follows: the first
documented evidence of local, regional or distant recurrence,
or recurrence of the tumour in the ipsilateral breast after
surgery. Death from any cause was the end point for overall
survival. SPSS version 10.0 software (SPSS Inc., Chicago, IL,
USA) was used to draw Kaplan-Meier DFS and OS curves.
Results
DFS and OS
In the TAM treatment group, 13 (11.0%) patients died and 18
(15.3%) suffered from recurrence. Among the non-TAM treated
patients, 42 (14.8%) died and 62 (21.8%) suffered recurrence.
The difference in DFS between the two groups of patients was
significant (p = 0.0058), whereas the difference in OS was not
(p = 0.0584). DFS and OS curves are shown in Figure 1.
Relationship between nodal status and TAM treatment
From the women in the TAM group who had positive axillary
lymph nodes, nine (14.8%) died and 14 (23%) suffered
recurrence, whereas from the women in the non-TAM group
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Figure 1. Kaplan-Meier plot for the tamoxifen (TAM) + cyclophosphamide, methotrexate and 5-fluorouracil (CMF) group and CMF-only
group. A) disease-free survival (DFS); B) overall survival (OS).
Table 2. Characteristics of eligible patients by treatment arm
Characteristics CMF CMF + TAM Total
No. of patients 284 118 402
Mean age, yr (range) 43.2 (24–53) 42.5 (24–53) 43.0 (24–53)
Clinical axillary nodal status, n (%)
   Negative 132 (46) 57 (48) 189 (47)
   Positive 152 (54) 61 (52) 213 (53)
Clinical tumour size, n (%)
   ≤ 2 cm 51 (18) 20 (17) 71 (18)
   2–5 cm 188 (66) 81 (69) 269 (67)
   > 5 cm 39 (14) 13 (11) 52 (13)
   Unknown 6 (2) 4 (3) 10 (2)
Stage, n (%)
    I 65 (23) 26 (22) 91 (23)
    II 187 (66) 75 (64) 262 (65)
    III 32 (11) 17 (14) 49 (12)
CMF = cyclophosphamide + methotrexate + 5-fluorouracil; TAM = tamoxifen.
who had positive lymph nodes, 36 (23.7%) died and 47 (30.9%)
had recurrences. For node-positive patients, the comparison
between the TAM and non-TAM groups showed that there
were significant differences in both DFS and OS (p = 0.0497
and p = 0.0285, respectively, Figure 2). For node-negative
patients, four (7.0%) patients in the TAM group died and four
(7.0%) suffered recurrence, while in the non-TAM treated
group, six (4.5%) died and 15 (11.4%) had recurrences. Among
the patients who had negative lymph nodes, the differences in
DFS or OS were not significant (p > 0.05, Figure 3).
Tolerability of TAM
Orally administered TAM 20 mg/day was well tolerated, with
excellent patient compliance. Of the 118 patients who received
TAM, 90 (76%) reported no side effects due to TAM. Fifteen
(13%) patients reported minor side effects such as hot flashes,
vaginal discharge and menstrual irregularities. Two patients
(< 2%) had ovarian cysts or uterine fibroids. There were no
major adverse events such as endometrial cancer in the TAM
group. Side effect data on 11 patients in our study were
missing.
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Discussion
In the 1960s and 1970s, several individual small trials found
that oophorectomy could improve DFS and OS in
premenopausal women with breast cancer, but as yet, there are
no large clinical trials supporting the use of ovarian ablation
and chemotherapy in young women.3 In 1992, an overview
suggested an advantage for the combination of chemotherapy
with oophorectomy compared with chemotherapy alone in
premenopausal patients with ER-positive tumours.4 Many
studies on endocrine therapy in premenopausal patients with
ER-positive tumours have been conducted. As chemotherapy
was considered the standard therapy for such premenopausal
patients for many years, there are few trials comparing
endocrine therapy alone (such as TAM) to chemotherapy plus
endocrine therapy. To investigate whether TAM added to the
benefits achieved with chemotherapy in younger patients, we
retrospectively studied 402 premenopausal women with ER-
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Figure 3. Kaplan-Meier plot for the tamoxifen (TAM) + cyclophosphamide, methotrexate and 5-fluorouracil (CMF) group and CMF-only
group in axillary lymph node-negative patients. A) disease-free survival (DFS); B) overall survival (OS).
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Figure 2. Kaplan-Meier plot for the tamoxifen (TAM) + cyclophosphamide, methotrexate and 5-fluorouracil (CMF) group and CMF-only
group in axillary lymph node-positive patients. A) disease-free survival (DFS); B) overall survival (OS).
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positive breast cancer recruited between January 1990 and
December 1999.
TAM has been used in the treatment of breast cancer since
the 1970s. TAM has a similar structure to oestrogen and its
anti-tumour mechanism is due to its anti-oestrogen effect. For
postmenopausal patients with ER-positive tumours, the use
of TAM improved survival, whereas the efficacy of adjuvant
TAM in premenopausal patients is unconfirmed. Overviews in
1985 and the 1990s showed that TAM did not offer additional
benefits to adjuvant chemotherapy in premenopausal patients.
However, in these two overviews, several chemotherapy
regimens were used and the durations of TAM administration
were less than 2 years.5,6 For many patients in the two overviews,
ER status was not available.
In our study, we used a CMF regimen for all premenopausal
patients with ER-positive tumours. The duration of TAM
therapy was longer than 2 years. Our data showed that
administration of TAM 20 mg/day for longer than 2 years
improved DFS but not OS. Further analysis showed that for
axillary lymph node-positive patients, TAM significantly
improved DFS and OS, while for lymph node-negative patients,
TAM did not result in additional benefits to the adjuvant CMF
regimen. This apparent difference in data may be related to
insufficient statistical power because of fewer events in node-
negative patients.
From our study, together with the two overviews mentioned
above, we conclude that TAM can be effective in both
postmenopausal and premenopausal women with ER-positive
tumours, but for premenopausal women, the duration of
TAM therapy is clearly critical. Due to higher concentrations
of oestrogen in premenopausal than in postmenopausal
patients, the effects of TAM is virtually nonexistent during the
first 1 or 2 years; the longer the duration of TAM therapy in
our study, the better the oestrogen blockade exhibited for
premenopausal patients than in those from the mentioned
overviews. This partly explains why TAM worked in the
premenopausal women in our study but not in those of the
overviews.
The reported side effects of TAM included hot flashes,
vaginal discharge, menstrual irregularities, ovarian cysts,
uterine fibroids, decreased bone mineral density and others.
Very few patients may suffer from endometrial cancer due to
long-term use of TAM, and few patients developing toxicities
require therapy cessation.7–9 On the other hand, TAM decreases
the risk of contralateral breast cancer.10 In our study, no
patient developed severe TAM toxicity and no patient ceased
TAM therapy because of its side effects. TAM can be safely used
in premenopausal breast cancer patients.
At present, the appropriate duration of TAM therapy is 5
years. In the early 1990s, the suggested duration of adjuvant
TAM therapy was 2 to 3 years, and we treated our patients with
3 years of TAM.11,12 Our study showed that the administration
of TAM 20 mg/day for 3 years resulted in additional benefits
to the CMF regimen in premenopausal women with node-
positive, ER-positive tumours. However, those with node-
negative, ER-positive tumours did not obtain additional
benefits. Our data indicate that the combination of TAM with
CMF polychemotherapy is clinically valuable for a subgroup
of premenopausal patients.
Luteinizing hormone-releasing hormone (LHRH)
analogues offer a different approach to the management of
breast cancer in premenopausal women. The most widely
studied LHRH analogue is goserelin. It acts on the
hypothalamic-pituitary axis to suppress ovarian function,
decreasing luteinizing hormone and estradiol levels to
postmenopausal values. Pooled data from 228 premenopausal
and perimenopausal patients with advanced breast cancer
enrolled in 29 studies worldwide demonstrated an objective
response rate for goserelin 3.6 mg of 36.4%, with a median
duration of response of 44 weeks.13,14 By virtue of its mode of
action, goserelin does not stimulate the ovaries and is unlikely
to have detrimental effects on the endometrium. Goserelin is
generally well tolerated. Preliminary results indicate that
goserelin might be effective in the adjuvant setting. To further
demonstrate the conclusion in our study as well as goserelin’s
role in the adjuvant setting, we are preparing to conduct a
prospective clinical trial to observe the effects of TAM
administration for 5 years plus combination chemotherapy
and 2 or 3 years of goserelin therapy in premenopausal women
with early breast cancer.
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